To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with recurrent anaplastic astrocytoma or with recurrent glioblastoma multiforme

Inclusion Criteria:

• Histologically diagnosed recurrent anaplastic astrocytoma or recurrent glioblastoma multiforme
• At least 18 years of age
• Performance status of 0 and 1 on the Eastern Cooperative Oncology Group (ECOG) criteria
• One or more measurable disease
• Adequate hematologic (neutrophil count >= 1500/uL, platelets >= 100,000/uL), hepatic (transaminase =< upper normal limit (UNL)x2.5, bilirubin level =< UNLx1.5, alkaline phosphatase =< UNLx2.5), and renal (creatinine clearance >= 30mL/min)
• Expected life time more than at least 2 months
• A patients who signed the informed consent prior to the participation in the study

Exclusion Criteria:

• A pregnant or lactating patient
• A patient of childbearing potential without being tested for pregnancy at baseline or with a positive test. (A premenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.)
• A man or woman of childbearing potential without the willingness to use a contraceptive measures during the study
• A patient with history of another malignant disease within past 3 years, except curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and early gastric cancer
• Medically uncontrolled serious heart, lung, neurological, psychological, or metabolic disease
• Uncontrolled serious infection
• Enrollment in other study within 30 days
• Hemorrhage on baseline radiologic examination
• A patient who refused to sign the informed consent